Ever Fortune. AI Co

Ever Fortune. AI Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Ever Fortune. AI Co (6841.TWO) as of Oct 21, 2026 is 0.49. In the previous year, Net Debt to Free Cash Flow Ratio was 30.25 — a change of -98.37% (lower).

Net Debt/FCF

0.49

YoY

-98.37%

Last updated:

Net Debt to Free Cash Flow Ratio of Ever Fortune. AI Co is 2024 0.49 . Net Debt to Free Cash Flow Ratio of Ever Fortune. AI Co was 2023 30.25 . It decreases by -98.37% lower compared to the previous year.

The Ever Fortune. AI Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
46.82 TWD
Jan 1, 2019
-0.08 TWD
Jan 1, 2020
32.33 TWD
Jan 1, 2021
17.38 TWD
Jan 1, 2022
17.60 TWD
Jan 1, 2023
30.25 TWD
Jan 1, 2024
0.49 TWD
The Ever Fortune. AI Co Net Debt/FCF history
YEARNet Debt/FCFYoY
0.49-98.37%
30.25+71.94%
17.60+1.24%
17.38-46.24%
32.33-38,278.81%
-0.08-100.18%
46.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ever Fortune. AI Co Stock analysis

What does Ever Fortune. AI Co do? Ever Fortune.AI Co., Ltd. generates revenue through the sale of medical AI software products and customized technology solutions. The company offers medical big data platforms, cloud biomedical services, and AI-driven tools such as the radiographic bone age-assisted interpretation system, ultrasound breast tumor auxiliary classification system, and CT liver cancer metastasis risk management system. These products target healthcare providers, hospitals, and medical institutions seeking advanced diagnostic and analytical capabilities. The firm's focus on specialized medical AI applications ensures consistent demand from clients requiring precision in radiology, oncology, and cardiology. The company's revenue streams include the provision of medical AI data analysis services and tailored AI technology solutions for healthcare facilities. Products like the liver fibrosis evaluation system and irregular cardiac fibrillation interpretation system are designed to address specific clinical needs, enhancing diagnostic accuracy. Healthcare organizations, particularly those in radiology and cardiology departments, purchase these tools to improve patient outcomes and operational efficiency. Ever Fortune.AI's business model centers on delivering high-value AI solutions for medical diagnostics, with a portfolio that includes both standardized products and custom-developed systems. The firm's offerings cater to hospitals and medical institutions looking to integrate AI into their diagnostic workflows. By focusing on niche medical applications, the company establishes itself as a specialized provider in the healthcare technology sector. Ever Fortune. AI Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ever Fortune. AI Co stock

Net Debt to Free Cash Flow Ratio of Ever Fortune. AI Co is 0.49 in 2024.

Net Debt to Free Cash Flow Ratio of Ever Fortune. AI Co changed from 30.25 to 0.49, representing a -98.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Ever Fortune. AI Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Ever Fortune. AI Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Ever Fortune. AI Co

All Key Metrics — Ever Fortune. AI Co